CARSgen Wins China’s Fifth CAR-T Approval But Pricing Dilemma Unresolved

 
• By Dexter Jie Yan
  
patient access
CARSgen and partner Huadong face formidable task to expand patient access to their CAR-T therapy • Source: Shutterstock

More from China

More from Focus On Asia